General Information:

Id: 3,346
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Obesity - [OMIM]
Mus musculus
male
diet-induced obesity (DIO) C57BL/6 mouse
article
Reference: Veniant MM et al.(2009) Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice Diabetes Obes Metab 11: 109-117 [PMID: 18479468]

Interaction Information:

Comment Corticosterone circadian rhythm was similar between lean and DIO C57BL/6 mice, and 11beta-HSD1 enzyme activity undergoes minimal variations throughout the day.
Formal Description
Interaction-ID: 30739

affects_quantity of

drug/chemical compound

Corticosterone

Comment Corticosterone circadian rhythm was similar between lean and DIO C57BL/6 mice, and 11beta-HSD1 enzyme activity undergoes minimal variations throughout the day.
Formal Description
Interaction-ID: 30740

affects_activity of

gene/protein

HSD11B1

Drugbank entries Show/Hide entries for HSD11B1
Comment Corticosterone circadian rhythm was similar between lean and DIO C57BL/6 mice, and 11beta-HSD1 enzyme activity undergoes minimal variations throughout the day.
Formal Description
Interaction-ID: 30741

gene/protein

HSD11B1

increases_quantity of

drug/chemical compound

Corticosterone

Drugbank entries Show/Hide entries for HSD11B1
Comment The 11beta-HSD1 inhibitor, compound 2922, exhibited maximum efficacy if dosed in the afternoon when plasma corticosterone is high; the morning dosing when plasma corticosterone is low did not lead to efficacy.
Formal Description
Interaction-ID: 30742

drug/chemical compound

Compound 2922

decreases_activity of

gene/protein

HSD11B1

in white adipose tissue
Drugbank entries Show/Hide entries for HSD11B1
Comment The 11beta-HSD1 inhibitor, compound 2922, exhibited maximum efficacy if dosed in the afternoon when plasma corticosterone is high; the morning dosing when plasma corticosterone is low did not lead to efficacy.
Formal Description
Interaction-ID: 30743

affects_activity of

drug/chemical compound

Compound 2922

Comment Treatment with compound 2922 resulted in the reduction of acetyl-coenzyme A (CoA) carboxylase and fatty acid synthase expression levels in the liver, suggesting that there was decreased lipogenesis in 11beta-HSD1 inhibitor-treated animals.
Formal Description
Interaction-ID: 30744

drug/chemical compound

Compound 2922

decreases_expression of

gene/protein

ACACA

in liver
Drugbank entries Show/Hide entries for ACACA
Comment Treatment with compound 2922 resulted in the reduction of acetyl-coenzyme A (CoA) carboxylase and fatty acid synthase expression levels in the liver, suggesting that there was decreased lipogenesis in 11beta-HSD1 inhibitor-treated animals.
Formal Description
Interaction-ID: 30745

drug/chemical compound

Compound 2922

decreases_expression of

gene/protein

FASN

in liver
Drugbank entries Show/Hide entries for FASN
Comment Treatment with compound 2922 resulted in the reduction of acetyl-coenzyme A (CoA) carboxylase and fatty acid synthase expression levels in the liver, suggesting that there was decreased lipogenesis in 11beta-HSD1 inhibitor-treated animals.
Formal Description
Interaction-ID: 30746

drug/chemical compound

Compound 2922

decreases_activity of

in liver
Comment Sterol-CoA desaturase 1 expression was reduced in the 25 mg/kg q.d. PM and 12.5 mg/kg b.i.d. (twice a day) groups.
Formal Description
Interaction-ID: 30747

drug/chemical compound

Compound 2922

decreases_expression of

gene/protein

SCD

in liver
Comment Diacylglycerol acyltransferase 1 expression level was increased in the 25 mg/kg q.d. PM and 12.5 mg/kg b.i.d. (twice a day) groups.
Formal Description
Interaction-ID: 30748

drug/chemical compound

Compound 2922

increases_expression of

gene/protein

DGAT1

in liver
Comment Inhibition of 11beta-HSD1 in the liver led to reduced free fatty acid synthesis.
Formal Description
Interaction-ID: 30749

drug/chemical compound

Compound 2922

decreases_activity of

in liver